Loading clinical trials...
Loading clinical trials...
Cultural Adaptation of Cognitive Behavioral Therapy for Insomnia for the Arab World
The goal of this clinical trial is to learn whether culturally adapted versions of Cognitive Behavioral Therapy for insomnia (CBTi) can reduce insomnia severity and improve sleep and mood outcomes in Arab adults with insomnia. The main questions it aims to answer are: Does culturally adapted CBTi (surface-level or surface + deep-level adaptations) reduce insomnia severity compared to a wait-list control condition? Are there differences in treatment efficacy between surface-level adaptations and combined surface + deep-level cultural adaptations of CBTi? Researchers will compare surface-level adapted CBTi, surface + deep-level adapted CBTi, and a wait-list control group to see if culturally adapted CBTi improves insomnia symptoms, sleep parameters, dysfunctional beliefs about sleep, anxiety, depression, and fatigue. Participants will: Be randomly assigned to one of three groups: surface-level adapted CBTi, surface + deep-level adapted CBTi, or a wait-list control Receive a culturally adapted CBTi intervention or remain on a wait-list during the study period Complete self-report questionnaires assessing insomnia severity, sleep beliefs, mood, and fatigue Complete sleep diaries at multiple time points across the study duration
Insomnia is a common sleep problem that affects how people fall asleep, stay asleep, and feel during the day. One of the most effective non-medication treatments for insomnia is Cognitive Behavioral Therapy for Insomnia (CBTi). CBTi helps people change unhelpful thoughts and behaviors related to sleep. However, most CBTi programs have been developed and tested in Western countries, and much less is known about how well they work for people from other cultural backgrounds. Research has shown that individuals from southern cultures, including Arab populations, are often underrepresented in mental health research. This gap is important because culture influences how people understand health problems, seek help, and engage with treatment. Two key findings motivated the current study. First, earlier research found that Syrians showed lower engagement in CBTi, suggesting that standard CBTi may not fully meet the needs of Arab clients. Second, our own qualitative research showed that Arabs often understand sleep and insomnia in culturally specific ways. For example, insomnia is commonly described as a mental or cognitive issue-often referred to as "overthinking"-rather than as a purely biological sleep disorder. Many people also hold social or spiritual explanations for insomnia, such as the belief that sleep problems may be caused by the evil eye or reflect a lack of faith. These beliefs can influence whether and how individuals seek help, with many turning to spiritual practices rather than psychological treatments. Together, these findings suggest that tailoring CBTi to Arab cultural beliefs and practices may improve its relevance and effectiveness. To guide this process, the study used the Cultural Treatment Adaptation Framework (CTAF), a research-based model that distinguishes between surface-level adaptations, which focus on how treatment is delivered (for example, language, format, and engagement strategies), and deep-level adaptations, which modify core elements of treatment to reflect cultural values, beliefs, and explanatory models of illness. This pilot randomized controlled trial aimed to compare: 1. A surface-adapted version of CBTi (S-CBTi) 2. A combined surface- and deep-adapted version of CBTi (SD-CBTi) 3. A wait-list control condition (WL) The main goal was to examine whether culturally adapted CBTi improves insomnia symptoms among Arab adults and whether adding deep-level cultural adaptations provides additional benefits beyond surface-level changes alone. The study tested two main hypotheses: 1. Both adapted CBTi programs would reduce insomnia severity more than the wait-list condition. 2. The combined surface- and deep-adapted CBTi would lead to greater improvements than the surface-adapted CBTi alone. The study was a single-blind randomized controlled trial, meaning that participants did not know which version of treatment they were receiving, but the therapist did. Participants were recruited between September 2022 and June 2023 through social media and referrals from a sleep clinic in Cairo, Egypt. Ethical approval was obtained from the Université Laval Research Ethics Committee, and all participants provided written informed consent before taking part. The study followed internationally recognized guidelines for conducting and reporting clinical trials. Participants were randomly assigned to one of three groups in equal numbers. An independent statistician ensured that the group assignment process was concealed until all participants had been enrolled. Outcomes were measured at four time points: before treatment began, halfway through treatment, immediately after treatment, and three months later. Adults aged 18 and older were eligible if they identified as Arab, spoke Arabic, and had parents and grandparents raised in an Arab cultural context, including countries in North Africa, the Middle East, and the Arabian Peninsula. Participants had to meet diagnostic criteria for insomnia and report at least moderate insomnia symptoms. People who worked night shifts, used sleep-altering medications, had certain untreated mental health or sleep disorders, or used cannabis frequently were excluded to ensure participant safety and clarity of results. Both CBTi programs consisted of six group sessions delivered over eight weeks via videoconference, reflecting participants' preference for online treatment and reducing barriers related to access and stigma. Sessions were conducted in Arabic by a bilingual therapist of Arab origin who was trained in CBTi and intercultural clinical practice. Groups included 5 to 8 participants. Participants in the wait-list group did not receive treatment during the first eight weeks but were offered the culturally adapted CBTi afterward. Surface-level adaptations focused on improving engagement and accessibility. The program was presented as a sleep-focused intervention rather than a mental health treatment to reduce stigma. Participants received reminders between sessions and were encouraged to contact the research team for support. Sessions followed standard CBTi principles, with equal emphasis on cognitive and behavioral strategies, and the therapist used a more directive style. In addition to the surface-level changes described above, the SD-CBTi program incorporated deep cultural adaptations. These adaptations addressed how insomnia is understood and experienced within Arab cultures. * A culturally relevant explanation of insomnia that emphasized overthinking, social stressors, and spiritual meanings, rather than relying solely on Western biomedical models. * Integration of collectivist values through group discussion, shared experiences, and educational materials designed for family members. * Adaptations to sleep hygiene recommendations that considered co-sleeping, prayer practices, herbal remedies, and common sleep patterns such as daytime napping. * Gradual sleep restriction and flexible scheduling to accommodate religious practices, social obligations, and weekends. * Cognitive strategies that directly addressed culturally shaped beliefs, such as the idea that insomnia reflects weak faith. * Inclusion of spiritual practices, such as brief breathing exercises followed by prayer, at the end of sessions. * Discussion of culturally relevant situations that may disrupt sleep, including Ramadan, seasonal changes, and family responsibilities. The therapist adopted a less directive, more collaborative style in this condition, and sessions were slightly longer to allow space for discussion and reflection. The primary outcome was insomnia severity, measured using a validated Arabic version of the Insomnia Severity Index (ISI). Improvements were considered clinically meaningful if participants showed a substantial reduction in symptoms or no longer met criteria for insomnia. Secondary outcomes included: * Beliefs and attitudes about sleep * Anxiety and depression symptoms * Fatigue * Objective sleep patterns reported in daily sleep diaries, such as time to fall asleep and total sleep time These measures allowed researchers to examine not only whether sleep improved, but also whether participants felt better emotionally and functioned better during the day. The study used statistical methods that included all participants as originally assigned, even if they did not complete every assessment. This approach reflects real-world treatment conditions. Analyses compared changes over time between the three groups and examined whether improvements were maintained at the three-month follow-up. This study addresses an important gap in sleep and mental health research by focusing on Arab populations, who are often overlooked in clinical trials. By systematically testing cultural adaptations to CBTi, the study helps clarify whether and how evidence-based treatments can be tailored for different cultural contexts. The findings have the potential to inform more inclusive, culturally responsive sleep interventions and improve access to effective insomnia treatment for Arab communities worldwide.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Neuromed Clinic
Laval, Quebec, Canada
Start Date
September 1, 2022
Primary Completion Date
September 20, 2022
Completion Date
December 23, 2023
Last Updated
January 13, 2026
54
ACTUAL participants
Surface+deep level adaptations
BEHAVIORAL
Surface level adaptation
BEHAVIORAL
Lead Sponsor
Laval University
NCT06032377
NCT06807086
NCT06181643
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions